Navigation Links
Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009

LONDON, November 11 /PRNewswire/ -- Extensive research conducted by the Imperial College of London, Ghent University Hospital and University of Sheffield on the Simbionix PROcedure Rehearsal Studio(TM), was awarded a Magna Cum Laude EPOS Award at the CIRSE 2009 congress in Lisbon, Portugal.

The PROcedure Rehearsal Studio(TM), introduced by Simbionix last year, is the world's first patient specific system to enable clinicians to create practice scenarios based on their patient's unique anatomy as reconstructed from CTA or MRA data.

Preliminary data from ongoing research by the European Virtual Reality Endovascular Research Team (EVEResT) suggests that patient-specific rehearsal may enhance the performance of interventionalists in subsequent endovascular procedures. The preliminary data also suggested that after rehearsal, endovascular surgery is carried out more rapidly with less use of contrast and fluoroscopy and to a higher qualitative standard, compared to those interventions preceded by a generic warm-up case, or no warm-up at all.

Professor Nick Cheshire, Professor of Vascular Surgery at Imperial College remarks: "We are pleased to report on the strong correlation between the virtual and real operation with regards to the angiography images, endovascular access and material used during the intervention. The Rehearsal Studio was able to adequately predict the optimal material for the specific case at hand. Further research into the PROcedure Rehearsal Studio(TM) is expected to determine if this technology can indeed help to improve the technical skills of the interventionalist and tailor these skills to the challenges of a specific patient. The preliminary results already demonstrate shorter procedure time with less use of contrast; the end goal of the application of this technique will of course be to enhance patient safety and outcome."

Mr. Ran Bronstein, President and COO at Simbionix adds: "We are very pleased with the results of the research work conducted on our newest system. The PROcedure Rehearsal Studio(TM) is an innovative product that utilizes a unique technology which was developed following intensive R&D efforts. Based on initial reactions, I believe it will change the way physicians practice and perform today."

About Imperial College Londonthe EVEResT Research Group

The EVEResT research group, led by Professor N. Cheshire, is a multicenter collaboration between the Imperial College London in the U.K., the University Hospital Ghent in Belgium (Prof. F. Vermassen) and the Sheffield Vascular Institute in the U.K.(Prof. P. Gaines).

The research group is multidisciplinary in nature, consisting of vascular surgeons, radiologists and cardiologists. Its main goal is to provide a platform for research into medical simulation and to aid the process of validation and implementation of endovascular simulation as both a training, credentialing and procedure rehearsal tool.

About Simbionix USA Corporation

Simbionix is the leader in the development and delivery of innovative and effective virtual reality simulation products and solutions for clinical education and training of medical professionals. The products are designed to accelerate best-practice medical training, advance clinical performance, and improve patient safety.

The Simbionix product line includes the ANGIO Mentor(TM) line for endovascular procedures, LAP Mentor(TM) line for laparoscopic surgical procedures, GI Mentor(TM) for upper and lower gastrointestinal procedures and the URO Mentor(TM) for urological procedures. In addition, Simbionix distributes the HystSim(TM) for hysteroscopic procedures. Each simulation platform is a leading simulator in the relevant clinical area.

Simbionix simulation products have been validated in several scientific studies and the company cooperates closely with both industry and leading medical institutions to develop the most advanced simulators for the training and assessment of medical professionals.

    Galia Zilbershtein-Salant
    Exhibition Manager
    Tel: +972-8-9211177

SOURCE Simbionix Ltd.

SOURCE Simbionix Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Emotions increase or decrease pain: researchers
2. Quick Defense(R) by Gaia Herbs Offers Research-Based, Patent-Pending Technology for a Fast Response in Supporting the Immune System
3. Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research
4. Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits
5. U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain
6. Researchers show how to divide and conquer social network of cells
7. Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls
8. St. Jude Childrens Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial
9. Connection between depression and osteoporosis detailed by Hebrew University researchers
10. Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill
11. Congressman Fattah Supports Legislation to Address More Funds for Pancreatic Cancer Research
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology: